March 2026 in “SKIN The Journal of Cutaneous Medicine” The Phase 2 LILAC study (N=132) demonstrated the efficacy of litifilimab in reducing disease activity in patients with active cutaneous lupus erythematosus (CLE), as measured by the CLASI-A score, which evaluates five clinical subcomponents: Erythema, Scale/Hypertrophy, Mucous Membrane Lesions, Recent Hair Loss, and Non-scarring Alopecia. Significant improvements were observed at Week 16, particularly in sunlight-exposed areas, with up to 33.3% of participants showing a 1-point improvement in Erythema. The study confirmed that no single subcomponent solely drives the CLASI-A score, highlighting the importance of all subcomponents in assessing CLE disease activity.
31 citations
,
February 1982 in “Archives of dermatology” Etretinate was effective for certain skin conditions, but caused side effects like chapped lips, dry mucous membranes, and hair loss.
52 citations
,
March 2007 in “Dermatologic Therapy” The CLASI is a reliable tool for measuring the severity of cutaneous lupus erythematosus.
research Skin
2 citations
,
January 2011 in “Elsevier eBooks” Skin problems are common in Lupus patients and can indicate the disease's severity, requiring specific treatments and lifestyle changes.
32 citations
,
September 1989 in “Medical Clinics of North America” Skin problems are common in lupus, important for diagnosis, and can be triggered by sunlight.